Regeneron Pharmaceuticals Inc. (REGN)
Last updated: 2026-10-20 15:27:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Regeneron Pharmaceuticals Inc. (REGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $796.22, with a market capitalization of $81.41B and a P/E ratio of 18.60. Over the past 52 weeks, its price has ranged from $572.75 to $859.34. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$81.41B | |
$793.85 | |
$1,211.20 | |
$4.61 | |
$782.04 | |
168.25K | |
745.29K | |
18.60 | |
$859.34 | |
$572.75 | |
0.47% | |
2001-12-30 |
Regeneron Pharmaceuticals Inc. (REGN) Stock Price Today
Regeneron Pharmaceuticals Inc. (REGN) is currently trading at $796.22 as of 2026-10-20 15:25:00, up 1.81% ($14.18) from the previous close of $782.04
During today's regular trading session, REGN has traded between $4.61 and $1,211.20, with a trading volume of 168.25K shares. The current price is near the middle of today's range.
Regeneron Pharmaceuticals Inc. (REGN) 7-Day Stock Price Change
Over the past seven days, Regeneron Pharmaceuticals Inc. (REGN) moved from $746.54 to $796.22, representing a gain of 6.65% ($49.68).
The stock traded between $732.83 and $809.49 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 647.88 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
REGN 52-Week Price Position
Position in Range: 78.0%
REGN is currently trading at $796.22, placing it 78.0% of the way from its 52-week low of $572.75 to its 52-week high of $859.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Regeneron Pharmaceuticals Inc. (REGN)?
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Regeneron Pharmaceuticals Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15410 |
| CEO | Leonard S. Schleifer |
| Founded | 1988 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Regeneron Pharmaceuticals Inc. (REGN) Stock on MEXC
Eligible investors can buy real shares of Regeneron Pharmaceuticals Inc. (REGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Regeneron Pharmaceuticals Inc. (REGN) stock price today?
2.Is REGN stock going up or down today?
3.What is REGN pre-market price?
4.What is REGN after-hours price?
5.Is REGN stock trading now?
6.Where does REGN sit relative to its 52-week high and low?
7.What sector is Regeneron Pharmaceuticals Inc. in?
8.What is Regeneron Pharmaceuticals Inc.'s market capitalization and where is it listed?
9.How is REGN valued in terms of P/E ratio and EPS?
10.Does Regeneron Pharmaceuticals Inc. pay a dividend?
Explore More US Stocks
Search Stocks
REGN Stock Calculator
Estimate the value between REGN shares and USD.
REGN Shares to USD
1.00 REGN shares = 796.222 USD
Calculations are estimates based on the latest available price and are for reference only.


